latest news releases from the newsroom
Elekta and IMPAC Medical Systems Announce Sales Consulting Agreement
STOCKHOLM, Sweden, Oct. 6, 2004 (PRIMEZONE) -- Elekta, a world leading supplier of advanced and innovative radiation oncology and neurosurgery solutions and IMPAC Medical Systems, Inc. (Nasdaq:IMPCE), a leading provider of information technology solutions for oncology care announced today that they have entered into a Sales Consulting Agreement. Under the Agreement, Elekta will have rights to offer IMPAC's oncology information system products and services, including the recently released MOSAIQ(TM) (work in progress) Image-Enabled EMR (electronic medical record) in select markets around the world.
New lymphoma data support Antisoma's plans for AS1406
LONDON, Oct. 6, 2004 (PRIMEZONE) -- Cancer drug development company Antisoma plc (LSE:ASM) will today present further promising data for its targeted apoptosis drug AS1406. Speaking at the Human Antibodies and Hybridoma meeting in Dublin, Antisoma's Chief Scientific Officer Dr Nigel Courtenay-Luck will reveal new data from the US National Cancer Institute showing that mice with advanced lymphomas live significantly longer when treated with AS1406 and that this effect is maintained even at doses tenfold lower than those previously tested.
Converium Holding AG
Converium has taken notice of information on certain class action lawsuits
ZUG, Switzerland, Oct. 6, 2004 (PRIMEZONE) -- Converium has taken notice of information on certain class action lawsuits which apparently were filed in the United States District Court for the Southern District of New York on behalf of all securities purchasers of Converium Holding AG ("Converium" or the "Company") from December 11, 2001 through July 20, 2004, inclusive (the "Class Period"). The Company has not, thus far, been able to obtain the complaints from the court. Accordingly, details of the specific nature of the claims and damages sought are not yet available. The Company is not in a position to comment further at this stage.